NDAORALTABLETPriority Review
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Clinical Trials (5)
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Started Mar 2026
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Started Oct 2025
20 enrolled
ProteinuriaImmunoglobulin A (IgA) NephropathyFocal Segmental Glomerulosclerosis+1 more
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Started May 2023
48 enrolled
Immunoglobulin A Nephropathy
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Started Aug 2021
67 enrolled
Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A Nephropathy+2 more
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Started Dec 2020
Loss of Exclusivity
LOE Date
Mar 29, 2030
49 months away
Patent Expiry
Mar 29, 2030
Exclusivity Expiry
Sep 5, 2031
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9993461 | Mar 29, 2030 | U-3993 |